{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T08:49:44Z","timestamp":1785919784136,"version":"3.56.0"},"reference-count":13,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,8,5]]},"DOI":"10.7759\/cureus.113982","type":"journal-article","created":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T08:21:35Z","timestamp":1785918095000},"source":"Crossref","is-referenced-by-count":0,"title":["Continuation of Tarlatamab With Concomitant Radiotherapy for Oligoprogression in Extensive-Stage Small-Cell Lung Cancer: A Report of Two Cases"],"prefix":"10.7759","author":[{"given":"Ryosuke","family":"Masui","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shota","family":"Omori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takuya","family":"Ueno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kosaku","family":"Komiya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2307980","article-title":"Tarlatamab for patients with previously treated small-cell lung cancer","volume":"389","author":"Ahn MJ","year":"2023","unstructured":"Ahn MJ, Cho BC, Felip E, et al.. Tarlatamab for patients with previously treated small-cell lung cancer. N Engl J Med. 2023, 389:2063-75. 10.1056\/NEJMoa2307980","journal-title":"N Engl J Med"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2502099","article-title":"Tarlatamab in small-cell lung cancer after platinum-based chemotherapy","volume":"393","author":"Mountzios G","year":"2025","unstructured":"Mountzios G, Sun L, Cho BC, et al.. Tarlatamab in small-cell lung cancer after platinum-based chemotherapy. N Engl J Med. 2025, 393:349-61. 10.1056\/NEJMoa2502099","journal-title":"N Engl J Med"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.24.00553","article-title":"Sustained clinical benefit and intracranial activity of tarlatamab in previously treated small cell lung cancer: DeLLphi-300 Trial Update","volume":"42","author":"Dowlati A","year":"2024","unstructured":"Dowlati A, Hummel HD, Champiat S, et al.. Sustained clinical benefit and intracranial activity of tarlatamab in previously treated small cell lung cancer: DeLLphi-300 Trial Update. J Clin Oncol. 2024, 42:3392-9. 10.1200\/JCO.24.00553","journal-title":"J Clin Oncol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2021.03.207","article-title":"Small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up(\u2606)","volume":"32","author":"Dingemans AC","year":"2021","unstructured":"Dingemans AC, Fr\u00fch M, Ardizzoni A, et al.. Small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up(\u2606). Ann Oncol. 2021, 32:839-53. 10.1016\/j.annonc.2021.03.207","journal-title":"Ann Oncol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.21873\/anticanres.14105","article-title":"Nab-paclitaxel monotherapy for relapsed small cell lung cancer: retrospective analysis and review","volume":"40","author":"Nakao M","year":"2020","unstructured":"Nakao M, Fujita K, Suzuki Y, Arakawa S, Sakai Y, Sato H, Muramatsu H. Nab-paclitaxel monotherapy for relapsed small cell lung cancer: retrospective analysis and review. Anticancer Res. 2020, 40:1579-85. 10.21873\/anticanres.14105","journal-title":"Anticancer Res"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.21873\/anticanres.15998","article-title":"Efficacy and safety of paclitaxel\/nab-paclitaxel chemotherapy for patients with relapsed small cell lung cancer","volume":"42","author":"Matsui Y","year":"2022","unstructured":"Matsui Y, Yamada T, Morimoto K, et al.. Efficacy and safety of paclitaxel\/nab-paclitaxel chemotherapy for patients with relapsed small cell lung cancer. Anticancer Res. 2022, 42:4921-8. 10.21873\/anticanres.15998","journal-title":"Anticancer Res"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199901283400403","article-title":"Twice-daily compared with once-daily thoracic radiotherapy in limited small-cell lung cancer treated concurrently with cisplatin and etoposide","volume":"340","author":"Turrisi AT 3rd","year":"1999","unstructured":"Turrisi AT 3rd, Kim K, Blum R, et al.. Twice-daily compared with once-daily thoracic radiotherapy in limited small-cell lung cancer treated concurrently with cisplatin and etoposide. N Engl J Med. 1999, 340:265-71. 10.1056\/NEJM199901283400403","journal-title":"N Engl J Med"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2025.02.023","article-title":"Rapid intracranial response with tarlatamab in patients with untreated brain metastases from SCLC-a real-world case series: case report","volume":"20","author":"Zhang B","year":"2025","unstructured":"Zhang B, Shah KB, Parma M, et al.. Rapid intracranial response with tarlatamab in patients with untreated brain metastases from SCLC-a real-world case series: case report. J Thorac Oncol. 2025, 20:1131-8. 10.1016\/j.jtho.2025.02.023","journal-title":"J Thorac Oncol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1002\/rcr2.70615","article-title":"Discrepant intracranial and extracranial responses to tarlatamab in relapsed small-cell lung cancer with untreated brain metastases: a case report","volume":"14","author":"Hayashi E","year":"2026","unstructured":"Hayashi E, Kano H, Nakamura K, et al.. Discrepant intracranial and extracranial responses to tarlatamab in relapsed small-cell lung cancer with untreated brain metastases: a case report. Respirol Case Rep. 2026, 14:e70615. 10.1002\/rcr2.70615","journal-title":"Respirol Case Rep"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.00201","article-title":"Local consolidative therapy vs. maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer: long-term results of a multi-institutional, phase II, randomized study","volume":"37","author":"Gomez DR","year":"2019","unstructured":"Gomez DR, Tang C, Zhang J, et al.. Local consolidative therapy vs. maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer: long-term results of a multi-institutional, phase II, randomized study. J Clin Oncol. 2019, 37:1558-65. 10.1200\/JCO.19.00201","journal-title":"J Clin Oncol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2017.3501","article-title":"Consolidative radiotherapy for limited metastatic non-small-cell lung cancer: a phase 2 randomized clinical trial","volume":"4","author":"Iyengar P","year":"2018","unstructured":"Iyengar P, Wardak Z, Gerber DE, et al.. Consolidative radiotherapy for limited metastatic non-small-cell lung cancer: a phase 2 randomized clinical trial. JAMA Oncol. 2018, 4:e173501. 10.1001\/jamaoncol.2017.3501","journal-title":"JAMA Oncol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/j.cllc.2026.01.007","article-title":"Outcomes of concurrent radiotherapy with tarlatamab in extensive-stage small cell lung cancer from the DLL3 PanTUMOR database","volume":"27","author":"Kim D","year":"2026","unstructured":"Kim D, Blocker S, Cavalieri CC, et al.. Outcomes of concurrent radiotherapy with tarlatamab in extensive-stage small cell lung cancer from the DLL3 PanTUMOR database. Clin Lung Cancer. 2026, 27:252-258.e3. 10.1016\/j.cllc.2026.01.007","journal-title":"Clin Lung Cancer"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1016\/j.radonc.2023.110048","article-title":"Radiotherapy to reinvigorate immunotherapy activity after acquired resistance in metastatic non-small-cell lung cancer: a pooled analysis of two institutions prospective phase II single arm trials","volume":"190","author":"Popp I","year":"2024","unstructured":"Popp I, Vaes RD, Wieten L, et al.. Radiotherapy to reinvigorate immunotherapy activity after acquired resistance in metastatic non-small-cell lung cancer: a pooled analysis of two institutions prospective phase II single arm trials. Radiother Oncol. 2024, 190:110048. 10.1016\/j.radonc.2023.110048","journal-title":"Radiother Oncol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/516873-continuation-of-tarlatamab-with-concomitant-radiotherapy-for-oligoprogression-in-extensive-stage-small-cell-lung-cancer-a-report-of-two-cases","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T08:21:36Z","timestamp":1785918096000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/516873-continuation-of-tarlatamab-with-concomitant-radiotherapy-for-oligoprogression-in-extensive-stage-small-cell-lung-cancer-a-report-of-two-cases"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,5]]},"references-count":13,"URL":"https:\/\/doi.org\/10.7759\/cureus.113982","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8,5]]}}}